In the present study, CLB (17.5 μM) combined with an antiepileptic and concurrently histone deacetylation inhibiting VPA (0.5 mM) was used ex vivo in PBMCs isolated from 17 patients with CLL, to detect their combined effects on viability and apoptosis. The gene discussed is CLYBL; the disease is B-cell chronic lymphocytic leukemia.